These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

255 related articles for article (PubMed ID: 28809532)

  • 61. Improved treatment of pancreatic cancer by IL-12 and B7.1 costimulation: antitumor efficacy and immunoregulation in a nonimmunogenic tumor model.
    Pützer BM; Rödicker F; Hitt MM; Stiewe T; Esche H
    Mol Ther; 2002 Apr; 5(4):405-12. PubMed ID: 11945067
    [TBL] [Abstract][Full Text] [Related]  

  • 62. The role of programmed cell death-1 (PD-1) and its ligands in pediatric cancer.
    van Dam LS; de Zwart VM; Meyer-Wentrup FA
    Pediatr Blood Cancer; 2015 Feb; 62(2):190-197. PubMed ID: 25327979
    [TBL] [Abstract][Full Text] [Related]  

  • 63. The IFN-γ/PD-L1 axis between T cells and tumor microenvironment: hints for glioma anti-PD-1/PD-L1 therapy.
    Qian J; Wang C; Wang B; Yang J; Wang Y; Luo F; Xu J; Zhao C; Liu R; Chu Y
    J Neuroinflammation; 2018 Oct; 15(1):290. PubMed ID: 30333036
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Class II transactivator-induced MHC class II expression in pancreatic cancer cells leads to tumor rejection and a specific antitumor memory response.
    Ekkirala CR; Cappello P; Accolla RS; Giovarelli M; Romero I; Garrido C; Garcia-Lora AM; Novelli F
    Pancreas; 2014 Oct; 43(7):1066-72. PubMed ID: 24987872
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Ketogenesis Attenuates KLF5-Dependent Production of CXCL12 to Overcome the Immunosuppressive Tumor Microenvironment in Colorectal Cancer.
    Wei R; Zhou Y; Li C; Rychahou P; Zhang S; Titlow WB; Bauman G; Wu Y; Liu J; Wang C; Weiss HL; Evers BM; Wang Q
    Cancer Res; 2022 Apr; 82(8):1575-1588. PubMed ID: 35247887
    [TBL] [Abstract][Full Text] [Related]  

  • 66. MiR-195/-16 Family Enhances Radiotherapy via T Cell Activation in the Tumor Microenvironment by Blocking the PD-L1 Immune Checkpoint.
    Tao Z; Xu S; Ruan H; Wang T; Song W; Qian L; Chen K
    Cell Physiol Biochem; 2018; 48(2):801-814. PubMed ID: 30032144
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Establishment of Slice Cultures as a Tool to Study the Cancer Immune Microenvironment.
    Jiang X; Seo YD; Sullivan KM; Pillarisetty VG
    Methods Mol Biol; 2019; 1884():283-295. PubMed ID: 30465211
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Mirage or long-awaited oasis: reinvigorating T-cell responses in pancreatic cancer.
    Ware MB; El-Rayes BF; Lesinski GB
    J Immunother Cancer; 2020 Aug; 8(2):. PubMed ID: 32843336
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Deploying Immunotherapy in Pancreatic Cancer: Defining Mechanisms of Response and Resistance.
    Beatty GL; Eghbali S; Kim R
    Am Soc Clin Oncol Educ Book; 2017; 37():267-278. PubMed ID: 28561678
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Combined inhibition of CXCL12 and PD-1 in MSS colorectal and pancreatic cancer: modulation of the microenvironment and clinical effects.
    Suarez-Carmona M; Williams A; Schreiber J; Hohmann N; Pruefer U; Krauss J; Jäger D; Frömming A; Beyer D; Eulberg D; Jungelius JU; Baumann M; Mangasarian A; Halama N
    J Immunother Cancer; 2021 Oct; 9(10):. PubMed ID: 34607895
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Generation and Harnessing of Heterotypic Tumor-Stroma Spheroids to Study Cancer Immunosurveillance.
    Zboralski D; Frömming A
    Methods Mol Biol; 2019; 1884():269-281. PubMed ID: 30465210
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Bifunctional small molecules targeting PD-L1/CXCL12 as dual immunotherapy for cancer treatment.
    Cheng B; Wang W; Liu T; Cao H; Pan W; Xiao Y; Liu S; Chen J
    Signal Transduct Target Ther; 2023 Mar; 8(1):91. PubMed ID: 36854661
    [No Abstract]   [Full Text] [Related]  

  • 73. Carcinomas assemble a filamentous CXCL12-keratin-19 coating that suppresses T cell-mediated immune attack.
    Wang Z; Moresco P; Yan R; Li J; Gao Y; Biasci D; Yao M; Pearson J; Hechtman JF; Janowitz T; Zaidi RM; Weiss MJ; Fearon DT
    Proc Natl Acad Sci U S A; 2022 Jan; 119(4):. PubMed ID: 35046049
    [TBL] [Abstract][Full Text] [Related]  

  • 74. [Remaining a physician-how to escape the commercialization trap].
    Gerheuser F
    Anaesthesiologie; 2023 Mar; 72(3):195-198. PubMed ID: 36471173
    [No Abstract]   [Full Text] [Related]  

  • 75. Nanomaterials for cancer immunotherapy.
    Song W; Musetti SN; Huang L
    Biomaterials; 2017 Dec; 148():16-30. PubMed ID: 28961532
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Hepatoma-intrinsic CCRK inhibition diminishes myeloid-derived suppressor cell immunosuppression and enhances immune-checkpoint blockade efficacy.
    Zhou J; Liu M; Sun H; Feng Y; Xu L; Chan AWH; Tong JH; Wong J; Chong CCN; Lai PBS; Wang HK; Tsang SW; Goodwin T; Liu R; Huang L; Chen Z; Sung JJ; Chow KL; To KF; Cheng AS
    Gut; 2018 May; 67(5):931-944. PubMed ID: 28939663
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Targeted drug delivery to melanoma.
    Liu Q; Das M; Liu Y; Huang L
    Adv Drug Deliv Rev; 2018 Mar; 127():208-221. PubMed ID: 28939379
    [TBL] [Abstract][Full Text] [Related]  

  • 78. PD-L1 immune suppression in cancer: Tumor cells or host cells?
    Kleinovink JW; van Hall T; Ossendorp F; Fransen MF
    Oncoimmunology; 2017; 6(7):e1325982. PubMed ID: 28811961
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Synergistic and low adverse effect cancer immunotherapy by immunogenic chemotherapy and locally expressed PD-L1 trap.
    Song W; Shen L; Wang Y; Liu Q; Goodwin TJ; Li J; Dorosheva O; Liu T; Liu R; Huang L
    Nat Commun; 2018 Jun; 9(1):2237. PubMed ID: 29884866
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Nanoparticle-Mediated Trapping of Wnt Family Member 5A in Tumor Microenvironments Enhances Immunotherapy for B-Raf Proto-Oncogene Mutant Melanoma.
    Liu Q; Zhu H; Tiruthani K; Shen L; Chen F; Gao K; Zhang X; Hou L; Wang D; Liu R; Huang L
    ACS Nano; 2018 Feb; 12(2):1250-1261. PubMed ID: 29370526
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.